🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Canada regulator expects to complete Moderna COVID-19 vaccine approval in coming weeks

Published 2020-12-18, 10:56 p/m

Dec 18 (Reuters) - Canadian health regulator said it expects to complete the review on Moderna Inc's MRNA.O coronavirus vaccine in the coming weeks after the U.S. Food and Drug Administration approved its emergency use on Friday.

"There is still information and data to be provided by Moderna for review," the regulator said in a statement.

Health Canada said it cannot provide a definite timeline for the vaccine approval but expects the process to be completed in the coming weeks.

Canada on Tuesday also announced an agreement to receive early deliveries of the Moderna vaccine amid a surge of new cases that are forcing new health restrictions across the country. had begun the rolling submission of its vaccine candidate in Canada in October following positive early results from studies. week Canada's health ministry had approved Pfizer Inc (NYSE:PFE)'s PFE.N vaccine , developed with Germany's BioNTech SE 22UAy.DE .

It has also received applications for other experimental vaccines from AstraZeneca Plc AZN.L and Johnson & Johnson (NYSE:JNJ) JNJ.N .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.